Business Development

Mito Biopharma strategy is to develop its core lead compounds to early clinical development and proof of concept e.g. phase 1b.  Therein, the company anticipates to partner at the IND or later phases of clinical development with large pharma partners strategically oriented in prioritized therapeutic areas. Opportunistically, Mito Biopharma may also partner or establish collaborations in non-core areas of its platform technology which may include orphan indications, cancer and infectious disease.